SPONGIOUS FILLERS BASED ON COLLAGEN - HYDROXYAPATITE - EUGENOL ACETATE WITH THERAPEUTIC POTENTIAL IN BONE CANCER

Basit Öğe Kaydı
dc.authoridGurevich, Leonid/0000-0002-5777-2541
dc.authoridKaya, Durmus Alpaslan/0000-0003-3544-9214
dc.authoridFICAI, Anton/0000-0002-1777-0525
dc.authoridNeacsu, Ionela-Andreea/0000-0003-3197-6455
dc.contributor.authorVladu, Alina F.
dc.contributor.authorMarin, Stefania
dc.contributor.authorNeacsu, Ionela A.
dc.contributor.authorTrusca, Roxana D.
dc.contributor.authorKaya, Madalina G. Albu
dc.contributor.authorKaya, Durmus A.
dc.contributor.authorPopa, Ana-Maria
dc.date.accessioned2024-09-18T20:11:35Z
dc.date.available2024-09-18T20:11:35Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe aim of this study was to develop and characterize composite materials based on collagen, hydroxyapatite and eugenol acetate as new filler biomaterial for the reconstruction of the tissue damage arising after the resection in case of bone cancer. Composite gels consisting of collagen and hydroxyapatite in different proportions (Coll:HAp - 100:0; 70:30; 40:60 - w/w) and 0.5% eugenol acetate were lyophilized and spongious fillers were obtained. The fillers were characterized by water absorption, enzymatic degradation and examined by optical and scanning electron microscopy, EDS, FT-IR spectroscopy while eugenol acetate release from the compositions was also studied. The results showed that the filler with optimal composition (Coll-HAp - 40:60 w/w) completely degrade over about 48 hours, the release capacity being longer during the 144 hours. The complex results obtained from physical-chemical, morphological and eugenol acetate release profile evaluation for the designed composite materials based on collagen and hydroxyapatite testify these formulations as drug delivery systems with potential applications as fillers in orthopaedic field in bone cancer.en_US
dc.description.sponsorshipCarol Davila University of Medicine and Pharmacy - Ministry of Research and Innovation within PNCDI III [23PFE/17.10.2018]en_US
dc.description.sponsorshipThis paper was financially supported by Carol Davila University of Medicine and Pharmacy through Contract no. 23PFE/17.10.2018 funded by the Ministry of Research and Innovation within PNCDI III, Program 1 Development of the National RD system, Subprogram 1.2 - Institutional Performance - RDI excellence funding projects.en_US
dc.identifier.doi10.31925/farmacia.2020.2.17
dc.identifier.endpage321en_US
dc.identifier.issn0014-8237
dc.identifier.issn2065-0019
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85090722044en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage313en_US
dc.identifier.urihttps://doi.org/10.31925/farmacia.2020.2.17
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8960
dc.identifier.volume68en_US
dc.identifier.wosWOS:000527105400017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSoc Stiinte Farmaceutice Romaniaen_US
dc.relation.ispartofFarmaciaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcollagenen_US
dc.subjecthydroxyapatiteen_US
dc.subjecteugenol acetateen_US
dc.subjectbone canceren_US
dc.subjectfillersen_US
dc.titleSPONGIOUS FILLERS BASED ON COLLAGEN - HYDROXYAPATITE - EUGENOL ACETATE WITH THERAPEUTIC POTENTIAL IN BONE CANCERen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
689.74 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu